Combination of 5% cysteamine and 4% nicotinamide in melasma: Efficacy, tolerability, and safety.
J Cosmet Dermatol
; 23(5): 1703-1712, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38327114
ABSTRACT
BACKGROUND:
Melasma is a chronic dermatosis that impacts the patient's quality of life and can present considerable challenges in terms of effective treatment.OBJECTIVE:
To evaluate the effectiveness, tolerability, and safety of 5% cysteamine combined with 4% nicotinamide in female subjects with melasma.METHODS:
This single-center, single-arm, prospective, open-label study evaluated patients with melasma using a combination cream of 5% cysteamine and 4% nicotinamide in a progressive regimen (60 min in the first month, 120 min in the second month, and 180 min in the third month).RESULTS:
Overall, 35 treated subjects exhibited reduced modified Melasma Area and Severity Index (mMASI) (p < 0.001) and decreased MelasQoL scores (p < 0.001), accompanied by improved brightness, luminosity, homogeneity, and spot intensity (p < 0.001). Photographic and colorimetric analysis revealed smaller spots and improved homogeneity.LIMITATIONS:
Adherence to progressive daily treatment could not be evaluated long-term.CONCLUSION:
A combination cream comprising 5% cysteamine and 4% nicotinamide was effective, tolerable, and safe for treating melasma.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Índice de Gravidade de Doença
/
Niacinamida
/
Cisteamina
/
Combinação de Medicamentos
/
Melanose
Limite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
J Cosmet Dermatol
Assunto da revista:
DERMATOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Brasil